Dreem, the Digital Health Company specialized in Sleep Medicine, to provide headband for cutting-edge EDoN initiative
Dreem has joined Alzheimer’s UK’s global initiative, Early Detection of Neurodegenerative diseases (EDoN), as a consortium partner for three years. This partnership has brought the development of wearables to detect early Alzheimer’s and other neurodegenerative diseases a step closer to reality.
EDoN is an ambitious project spearheaded by Alzheimer’s Research UK, the UK’s leading dementia research charity. Bringing together global experts in data science, digital technology and neurodegeneration, EDoN aims to use smartphone apps and wearables like smart watches and headbands to develop digital ‘fingerprints’ of early disease that could transform dementia research efforts in the future.
Alzheimer’s can begin in the brain up to two decades before symptoms start to show. To give emerging new treatments the best chance of success, doctors need to be able to detect the disease as early as possible and intervene when these treatments could make the greatest difference to people’s lives.
Disrupted sleep is a common symptom of dementia. Subtle changes in sleep patterns may also be detectable long before cognitive decline starts to affect people’s everyday lives.
Dreem, a company based in California and Paris, merges sleep science and deep technology to create better sleep solutions. The Dreem 3 headband can monitor and analyse sleep through records of brain activity, movements and frequency.
The Dreem 3 headband will be included in the first version of the EDoN digital toolkit. Used alongside the Mezurio and Longevity apps and a fitbit activity tracker, it will be used to collect digital data from participants in existing research cohorts. The data from the version 1 EDoN toolkit will inform the development of initial machine learning models and shape future iterations of the toolkit.
This three-year partnership will see Dreem providing the Dreem3 devices for use in several EDoN studies across the world, including two studies in the UK, two in Australia and one in the US. The data collected from these longitudinal case-control cohorts will allow researchers to better characterise the early signs of diseases like Alzheimer’s through monitoring sleep.
Through the partnership, Dreem will be training participants using the Dreem 3 headband in research studies and providing technical and project management support as well as data management services.
Pierrick Arnal, Chief Science Officer at Dreem, said:
“By accelerating time-to-diagnosis, and improving the prevention and treatment effect of diseases, the identification of early disease biomarkers shapes the future of medicine. With EDoN, Dreem is proud to contribute to the early detection of Alzhiemer’s disease. A cross-team effort to transform dementia research and care - for the better.”
Mike Oldham, Director of EDoN at Alzheimer’s Research UK, said:
“Digital technologies such as wearables and smartphone apps are providing ever more opportunities for people, and their doctors, to understand and monitor their health. We are delighted to be working with Dreem as part of the first version of the EDoN toolkit, to help start the search for digital fingerprints that can detect early disease using inexpensive and non-invasive tools.
“EDoN will combine sleep data with up to 20 other measures that can be picked up with consumer technology as people go about their day-to-day lives. This is a highly scalable approach and one that has the potential to detect neurodegenerative diseases much earlier than we can today.”
- Founded in 2014, Dreem is a Digital Health Company specialized in Sleep Medicine. With its Digital Sleep Clinic, the team merges deep technology and sleep medicine to reshape sleep care.
- With over fourty proprietary patents and the largest EEG sleep database, Dreem has become one of the leading figures in sleep care and research. Dreem’s partners include a unique network of over three hundred academic and research partners (Harvard Medical School, Stanford School of Medicine, The University of Cambridge, Ecole Polytechnique, etc. ), including 10 of the largest pharmaceutical companies.
- With its Digital Sleep Clinic, the company extends the reach of care and advances sleep science with technologies that connect patients to experts and investigators. Dreem Labs, a tailored solution for researchers and investigators, is its clinically-validated sleep assessment solution for (remote) clinical trials. An ideal candidate for large-scale longitudinal studies, and a valuable tool to assess drug performance and guide clinical decision-making.
- For more information, visit https://dreem.com